| Grant ID | RP150574 |
| Awarded On | May 20, 2015 |
| Title | Turning on a Novel Tumor-Inhibiting Switch for Colorectal Cancer |
| Program | Academic Research |
| Award Mechanism | High Impact/High Risk |
| Institution/Organization | The University of Texas Health Science Center at San Antonio |
| Principal Investigator/Program Director | Rong Li |
| Cancer Sites | Colorectal |
| Contracted Amount | $200,000 |
| Lay Summary |
It is known that estrogen is associated with reduced incidence of colorectal cancer (CRC). Estrogen effects in general are mediated by two estrogen receptors called ER-alpha and ER-beta, which play different and even opposite roles in cancer. The CRC-reducing effect of estrogen has been largely attributed to the action of ER-beta. Because estrogen itself is unlikely to be clinically useful due to its known ER-alpha-mediated side effects, rallying the antitumor activity of ER-beta through ER-beta-specific pathways represents a promising approach for CRC treatment and prevention. In the current proposal, researchers with highly complementary expertise will determine whether a clinically safe E... |